CBI’s 3rd Edition Drug Pricing Transparency Congress

CBI’s 3rd Edition Drug Pricing Transparency Congress
September 27, 2018 | Philadelphia, PA
www.cbinet.com/drugpricing

Have you been keeping up with the various state drug pricing regulations that have been introduced and passed across the nation? Over the past year, states including Oregon, California, Nevada, Maryland, New York, Massachusetts and Vermont – to name a few – have introduced and/or enacted different laws and enforcement initiatives mandating the disclosure of drug pricing increases, introducing restrictions limiting Medicaid drug spending, requiring disclosure of company metrics and expenses, and other related pricing ballot initiatives.

CBI’s 3rd Edition Drug Pricing Transparency Congress convenes key industry stakeholders to discuss how the future of state drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices.

Register by Friday, September 21, 2018 and
receive $300* off the standard rate with discount code DCP300.

Featured Discussion Topics:

• State Drug Pricing Reporting Requirements and Interpretations — What You Need to Know Now to Ensure Reporting Compliance
• Implications of State Drug Pricing Transparency Laws on Policy
• Operational Best Practices Focused on Governance and Planning for the Future
• Oregon HB 4005 — Reporting Requirements Overview and Update
• California SB-17 — Implementation and Enforcement Update
• The Latest Developments for New York's Medicaid Drug Cap and the Impact of ICER on Drug Pricing
• The Impact of Transparency and Disclosure Legislation on Legal and Compliance Practices
• Federal Legislative Activity Update — Patients First Blueprint Review

Speaker Perspectives

• Brian A. Bohnenkamp, Partner, FDA & Life Sciences Practice, King & Spalding LLP
• Joanne Chan, Assistant General Counsel, Pharmaceutical Research and Manufacturers of America (PhRMA)
• Sarah diFrancesca, Partner, Cooley LLP
• Seth Lundy, Partner, King & Spalding LLP
• Angela Marcucci, Director of Global Policy, Pfizer Inc.
• Kendra Martello, Senior Director, Public Policy, Government Affairs & Public Policy, Mallinckrodt Pharmaceuticals
• William A. Sarraille, Partner, Sidley Austin LLP
• Vince Sampson, Partner, Cooley LLP
• Debbie A. Walters, Vice President, Assistant General Counsel, Pfizer Inc.
• Sabrina Yohai, Vice President, Policy, Access & Value, Corporate Legal, Vertex Pharmaceuticals
• Andrew Parks, Director, KPMG

Don't be left out of the critical conversation. Register by Friday, September 21, 2018 and receive $300* off the standard rate with discount code DCP300.

*Offer expires September 21, 2018; applies to standard rates only and may not be combined with other offers, category rates, and promotions or applied to an existing registration.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.